Published in Drug Law Weekly, October 13th, 2009
"The selection of a world-class CRO is an important milestone in our product development process and it underscores our commitment to advance ANAVEX 2-73 through Phase I clinical trials," said Dr. Herve de Kergrohen, CEO of ANAVEX. "We are moving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.